AIMS/HYPOTHESIS: We compared metabolic gene expression in adipose tissue and skeletal muscle from patients with type 2 diabetes and from well-matched healthy control subjects. We hypothesised that gene expression would be discordantly regulated when comparing the two groups. Our secondary aim was to determine the effect of Interleukin-6 (IL6) infusion on circulating adipokines and on gene expression in human adipose tissue. To do this we used real-time RT-PCR. METHODS: Both diabetic and control subjects underwent basal skeletal muscle and subcutaneous adipose tissue biopsies. A subset of these individuals underwent a 3-h infusion of recombinant human IL6 and had adipose tissue samples taken before and after infusion. RESULTS: The mRNA gene expression of suppressor of cytokine signalling (SOCS) 3, peroxisome proliferative activated receptor (PPAR) alpha/delta, PPAR gamma, coactivator 1, alpha (PPARGC1A), carnitine palmitoyltransferase 1B and solute carrier family 2 (facilitated glucose transporter), member 4 (formerly known as glucose transporter 4/GLUT4), was higher in adipose tissue, but lower in skeletal muscle of diabetic patients than in that of control subjects. In addition, uncoupling protein 1 (UCP1) gene was detected in the adipose tissue of some of the diabetic patients, but not in the control subjects. The following genes were increased by infusion of recombinant human IL6 in both groups: SOCS1/3, resistin, adiponectin, AMP-activated protein kinase-alpha-1 and PPARA. Plasma tumour necrosis factor alpha, adiponectin and resistin were all unaffected by IL6 infusion, but plasma resistin was lower in the diabetic subjects than in control subjects. CONCLUSIONS/ INTERPRETATION: The observation that PPARGC1A and the PPARs were upregulated in the adipose tissue of type 2 diabetic patients, along with the finding that adipose tissue from some patients with type 2 diabetes can express UCP1 mRNA, suggests that in these patients white adipose tissue may move towards a brown adipose tissue phenotype.
AIMS/HYPOTHESIS: We compared metabolic gene expression in adipose tissue and skeletal muscle from patients with type 2 diabetes and from well-matched healthy control subjects. We hypothesised that gene expression would be discordantly regulated when comparing the two groups. Our secondary aim was to determine the effect of Interleukin-6 (IL6) infusion on circulating adipokines and on gene expression in human adipose tissue. To do this we used real-time RT-PCR. METHODS: Both diabetic and control subjects underwent basal skeletal muscle and subcutaneous adipose tissue biopsies. A subset of these individuals underwent a 3-h infusion of recombinant humanIL6 and had adipose tissue samples taken before and after infusion. RESULTS: The mRNA gene expression of suppressor of cytokine signalling (SOCS) 3, peroxisome proliferative activated receptor (PPAR) alpha/delta, PPAR gamma, coactivator 1, alpha (PPARGC1A), carnitine palmitoyltransferase 1B and solute carrier family 2 (facilitated glucose transporter), member 4 (formerly known as glucose transporter 4/GLUT4), was higher in adipose tissue, but lower in skeletal muscle of diabeticpatients than in that of control subjects. In addition, uncoupling protein 1 (UCP1) gene was detected in the adipose tissue of some of the diabeticpatients, but not in the control subjects. The following genes were increased by infusion of recombinant humanIL6 in both groups: SOCS1/3, resistin, adiponectin, AMP-activated protein kinase-alpha-1 and PPARA. Plasma tumour necrosis factor alpha, adiponectin and resistin were all unaffected by IL6 infusion, but plasma resistin was lower in the diabetic subjects than in control subjects. CONCLUSIONS/ INTERPRETATION: The observation that PPARGC1A and the PPARs were upregulated in the adipose tissue of type 2 diabeticpatients, along with the finding that adipose tissue from some patients with type 2 diabetes can express UCP1 mRNA, suggests that in these patients white adipose tissue may move towards a brown adipose tissue phenotype.
Authors: R K Semple; V C Crowley; C P Sewter; M Laudes; C Christodoulides; R V Considine; A Vidal-Puig; S O'Rahilly Journal: Int J Obes Relat Metab Disord Date: 2004-01
Authors: Fernando Castro-Chavez; Vijay K Yechoor; Pradip K Saha; Javier Martinez-Botas; Eric C Wooten; Saumya Sharma; Peter O'Connell; Heinrich Taegtmeyer; Lawrence Chan Journal: Diabetes Date: 2003-11 Impact factor: 9.461
Authors: Cora Weigert; Katrin Brodbeck; Harald Staiger; Christiana Kausch; Fausto Machicao; Hans U Häring; Erwin D Schleicher Journal: J Biol Chem Date: 2004-03-17 Impact factor: 5.157
Authors: Sara García-Serrano; Inmaculada Moreno-Santos; Lourdes Garrido-Sánchez; Carolina Gutierrez-Repiso; Jose M García-Almeida; Juan García-Arnés; Jose Rivas-Marín; Jose L Gallego-Perales; Eva García-Escobar; Gemma Rojo-Martinez; Francisco Tinahones; Federico Soriguer; Manuel Macias-Gonzalez; Eduardo García-Fuentes Journal: Mol Med Date: 2010-11-05 Impact factor: 6.354
Authors: Iain J Gallagher; Camilla Scheele; Pernille Keller; Anders R Nielsen; Judit Remenyi; Christian P Fischer; Karim Roder; John Babraj; Claes Wahlestedt; Gyorgy Hutvagner; Bente K Pedersen; James A Timmons Journal: Genome Med Date: 2010-02-01 Impact factor: 11.117
Authors: Xiang-Li Wang; Fei-Yan Deng; Li-Jun Tan; Hong-Yi Deng; Yao-Zhong Liu; Christopher J Papasian; Robert R Recker; Hong-Wen Deng Journal: J Bone Miner Res Date: 2008-03 Impact factor: 6.741